ADARx Pharmaceuticals
ADRX
62 hedge funds and large institutions have $1.53B invested in ADARx Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 62 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
71.88% more ownership
Funds ownership: 0% → 71.88% (+72%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$484M |
| 2 |
SR One Capital Management
Wayne,
Pennsylvania
|
+$199M |
| 3 |
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$135M |
| 4 |
TCG Crossover Management
Palo Alto,
California
|
+$82.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$72.9M |
Top Sellers
ADRX Hedge Fund Activity: Q3 2026 in Review
62 of the 8,154 institutional investors tracked by Wall St. Rank reported a position in ADARx Pharmaceuticals (ADRX) for Q3 2026, worth a combined $1.53B.
Buyers outnumbered sellers: 62 funds opened new ADRX positions and 0 closed out — a net gain of 62 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $484M.
- 62 institutional investors held ADARx Pharmaceuticals (ADRX) as of Q3 2026, up from 0 in Q2 2026.
- Funds reported $1.53B of ADARx Pharmaceuticals stock for Q3 2026.
- 62 funds opened new ADARx Pharmaceuticals positions in Q3 2026 and 0 closed out, a net change of +62 holders.
- The largest ADARx Pharmaceuticals buyer in Q3 2026 was OrbiMed, an estimated $484M added.
Based on aggregated 13F filings for Q3 2026.